Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvaso and Dysport for Rosacea Erythema and Flushing
NCT03508869Terminated
- Sponsor
- Skin Laser & Surgery Specialists of New York and New Jersey
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Trial of brimonidine transdermal lotion and botulinum toxin type A in rosacea (3 arms), sponsored by Skin Laser & Surgery Specialists of New York and New Jersey. Primary endpoints: Efficacy Assessments for Erythema at 6 months and Efficacy Assessments for Flushing at 6 months. Started Sep 2016; status: terminated.
02
Drugs
brimonidine transdermal lotionbotulinum toxin type A
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT03508869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508869.